Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Feb 14;8(7):11259-11267.
doi: 10.18632/oncotarget.13298.

Endoscopic versus laparoscopic resection of gastric gastrointestinal stromal tumors: a multicenter study

Affiliations
Multicenter Study

Endoscopic versus laparoscopic resection of gastric gastrointestinal stromal tumors: a multicenter study

Wei-Jie Dai et al. Oncotarget. .

Abstract

Despite endoscopic resection has been performed to treat gastric gastrointestinal stromal tumor (GISTs). However, the safety and long-term outcomes remains controversial. This study aims to compare the safety and surgical outcomes of endoscopic versus laparoscopic resection of gastric GISTs. A total of 335 patients that were pathologically confirmed with gastric GISTs (tumor size ≤ 3.5 cm) were surgically treated with endoscopic resection (endoscopic group) or laparoscopic resection (laparoscopic group) in three institutions from March 1, 2011 to October 1 2014. These demographics, tumor characteristics, and outcomes were retrospectively analyzed for identification of outcomes and feasibility of endoscopic or laparoscopic resection. Of 335 patients, 262 and 73 patients underwent endoscopic and laparoscopic resection, respectively. The average tumor size was 1.33±0.78 cm in the endoscopic group and 1.97±0.93 cm in the laparoscopic group. The average operating time was 62.40±36.94 min in the endoscopic group and 112.81±55.69 cm in the laparoscopic group. Days of realimentation was 2.76±1.67 in the endoscopic group and 4.89±2.03 in the laparoscopic group. The average cost was $ 3246.01±1017.61 in the endoscopic group and $ 4884.81±1339.51 in the laparoscopic group. There was no postoperative mortality. Endoscopic resection for gastric GISTs is safe and feasible in tumors ≤ 3.5 cm. Because endoscopic resection showed good results with lower operating time, realimentation days, length of hospital stay and mean total cost, it is a minimally invasive and safe alternative approach which can achieve fast recovery and satisfactory outcomes for appropriately selected patients with gastric GISTs.

Keywords: endoscopic; gastric GISTs; laparoscopic; minimally invasive; resection.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart of patients inclusion and exclusion
Figure 2
Figure 2
A. Operating time (min) of patients by treatment options; B. Realimentation (days) of patients by treatment options; C. Length of hospital stay (days) of patients by treatment options; D. Mean cost ($) of patients by treatment options.

Similar articles

Cited by

References

    1. Zhuang C, Wang M, Qiu WQ, Xu J, Shen ZY, Cao H. [Clinicopathological features and management of gastrointestinal stromal tumors complicated with synchronous other alimentary malignant tumor] Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:234–238. - PubMed
    1. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. LANCET ONCOL. 2002;3:655–664. - PubMed
    1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. SCIENCE. 1998;279:577–580. - PubMed
    1. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. CANCER-AM CANCER SOC. 2005;103:821–829. - PubMed
    1. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. HUM PATHOL. 2008;39:1411–1419. - PubMed

Publication types

MeSH terms